NCT04812431View on ClinicalTrials.gov

Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

October 31, 2028

Study Completion Date

September 30, 2030

Conditions
Spinal Cord Injury, AcuteSpinal Cord Injury at C4 Level With Complete LesionSpinal Cord Injury at C5-C7 Level With Complete Lesion
Interventions
BIOLOGICAL

Neural precursor cells derived from human embryonic stem cell line

When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.

Trial Locations (2)

16499

RECRUITING

Ajou University Hospital, Suwon

03722

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
collaborator

Linical Co., Ltd.

INDUSTRY

collaborator

Yonsei University

OTHER

lead

S.Biomedics Co., Ltd.

INDUSTRY

NCT04812431 - Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI | Biotech Hunter | Biotech Hunter